66 results about "Neurogenesis" patented technology

Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.

A system and method for adaptive neural network architecture with real-time neurogenesis capabilities during inference operations. The system processes data through a core neural network with integrated supervisory and neurogenesis control systems. A hierarchical supervisory network, comprising low-level, mid-level, and high-level nodes, monitors network activity patterns and information flow. The neurogenesis control system maintains continuous activity maps, detects processing bottlenecks, and determines optimal placement of new neurons using geometric optimization. A modification subsystem implements controlled neurogenesis operations while maintaining network stability. The system handles data through adaptive codeword allocation and fusion of dissimilar data types. This sophisticated approach enables neural networks to dynamically expand their processing capacity during operation, responding to detected bottlenecks while maintaining operational stability through carefully managed integration of new neurons.

Disclosed are in vitro methods for the differentiation of precursor cells into a neural crest cell (NCC) primed to a neurogenic lineage. The methods may include, for example, the steps of activating a Hedgehog signaling pathway (“HH signaling pathway”) in a precursor cell, wherein the precursor cell may be contacted with a neural crest cell induction medium for differentiation of the precursor cell into a neural crest cell. Compositions for carrying out the disclosed methods are also disclosed.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

Disclosed in the present invention is a phosphatidylserine and docosahexaenoic acid (DHA) composite, and its application thereof in a functional preparation, belonging to the field of health-care food. By combining two substances in a specific ratio and further applying them to edible functional preparations, brain entry efficiency of unsaturated fatty acids including DHA is improved. The ratio verifies a synergistic interaction mechanism of two active ingredients. Phosphatidylserine promotes enrichment of fatty acids such as the DHA in a brain by enhancing permeability of a blood-brain barrier, promotes neurogenesis, and enhances learning and memory abilities. Moreover, combination of the phosphatidylserine (PS) and the DHA can significantly improve an expression level of neurotrophic factors and protect and repaire a nervous system. (Figl)

The invention provides a traditional Chinese medicine compound composition with a nerve repairing effect, a cell culture medium, a traditional Chinese medicine-neural stem cell exosome compound and application, and belongs to the technical field of biological medicine. Based on the basic theory of traditional Chinese medicine and the combined theory of traditional Chinese medicine and western medicine, the traditional Chinese medicine compound composition is provided and comprises gastrodia elata exosomes, astragalus membranaceus exosomes and resveratrol, the traditional Chinese medicine compound composition is prepared into a cell culture medium, neural stem cells are cultured through the cell culture medium, and the neural stem cells are obtained. Therefore, the traditional Chinese medicine-neural stem cell exosome compound with an efficient nerve repairing function is prepared. The traditional Chinese medicine-neural stem cell exosome compound achieves the purpose of comprehensively repairing nerve injury by precisely targeting nerve cells, promoting neurogenesis, repairing the function of a neural circuit and reducing the inflammatory effect, and can be used for preparing related medical instruments and drugs for nerve repair.

Novel populations of canine derived stem cells useful for treatment across allogeneic barriers. The stem cells can be of mesenchymal lineage optimized to possess enhanced proliferative activity in vitro and in vivo without significant loss of therapeutic functionality. Said therapeutic activities include angiogenesis, stimulation of growth factor production, antifibrotic effects, neurogenesis, immune modulation, and antiapoptotic effects.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

Provided is a technology capable of promoting neurogenesis. This neurogenesis promoter contains at least one of a substance that inhibits the glutaminolysis pathway and a substance that inhibits mTOR, and is used between postnatal day 0 and corrected age of 20 months of a premature infant.

The invention discloses application of human dental pulp stem cells in enhancing neurogenesis in a brain region and treating neurodegenerative diseases, including stem cells for enhancing neurogenesis of adult hippocampus, and the human dental pulp stem cells have the following functional characteristics: flow cytometry detection shows that the Netin positive rate is not lower than 90%, and the beta-tubulin III positive rate is not lower than 85%; in a conditioned culture medium after in-vitro culture for 24 hours, the secretion amount of BDNF reaches more than 500pg / mL / 106 cells, and the secretion amount of GDNF reaches more than 200pg / mL / 106 cells; the alizarin red dyeing positive area accounts for not less than 60% after osteogenesis induction, and the oil red O dyeing positive area accounts for not less than 50% after adipogenesis induction; according to the quantitative standard that the number of dentate gyrus DCX + newborn neurons of the adult hippocampus is increased by more than 50% compared with that before treatment, the dual-mechanism targeted therapy 1 specifically activates hippocampus neural stem cells and promotes newborn neurons to differentiate by highly expressing neural markers and secreting neurotrophic factors, so that the neurogenesis of the adult hippocampus is enhanced, and the neurogenesis of the adult hippocampus is enhanced. Meanwhile, A beta deposition and p-Tau phosphorylation are reduced.

The invention discloses a method for synergistically treating Alzheimer's disease through gene-modified human interdental stem cells, and belongs to the field of drug therapy. According to the method, healthy adult dental pulp mesenchymal stem cells (hDPSCs) are extracted, BDNF and NRF2 genes are introduced through lentiviral vectors, the BDNF and NRF2 genes have neurotrophic, antioxidant and anti-inflammatory capacities, and then the hDPSCs are combined with curcumin nanoparticles and injected to the hippocampus of an AD mouse through stereotactic injection. The BDNF can promote nerve regeneration, the NRF2 can improve oxidative stress and inflammation environment, and the curcumin nanoparticles regulate A beta metabolism and activate a BDNF signal channel. Experiments show that the combined therapy can significantly enhance hippocampal neurogenesis of AD mice and improve expression of neuron markers, and it is proved through Morse water maze tests that the combined therapy can improve the spatial learning and memory ability of the mice. The method breaks through the limitation of traditional single-target treatment, multi-dimensional pathological intervention is achieved, the stem cells are rich in source and high in safety, and a new strategy is provided for treatment of the Alzheimer's disease.

The invention discloses a traditional Chinese medicine active ingredient composition for treating cerebral infarction and application thereof, and relates to the technical field of traditional Chinese medicines. By optimizing the dosage ratio of the active ingredient compound (calycosin-7-glucoside, formononetin and astragaloside), it is proved that the compound remarkably relieves neurological impairment, reduces the cerebral infarction area, promotes neurogenesis after cerebral infarction and can effectively improve cerebral infarction prognosis, and the effect is equivalent to that of a clinical proved recipe 'Yang-tonifying and five-returning decoction'. The active ingredient composition obtained by the invention has the advantages of clear ingredients, definite mechanism and controllable quality, the safety of clinical medication is improved on the basis of ensuring the curative effect, the hidden danger of adverse reaction is reduced, and a modern compound traditional Chinese medicine which is compatible with active ingredients in a modern dosage form is favorably prepared.

This invention provides a pH-responsive immunomodulatory microneedle patch, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention incorporates Zif-8 nanoparticles loaded with ChABC into GelMA hydrogel to prepare a pH-responsive immunomodulatory microneedle patch (Z@C-MN). As the patch gradually degrades, the system can continuously release Zn in a pH-responsive manner. 2+ Z@C-MN, along with ChABC, promotes in situ repair of cerebral fibrosis (SCI) after injury. Z@C-MN induces macrophage polarization towards a pro-regenerative phenotype, thereby downregulating the inflammatory response, increasing neurite length, and promoting the differentiation of neural stem cells into neurons. In vivo, Z@C-MN reduced the inflammatory microenvironment after injury and promoted angiogenesis in a rat SCI model. Furthermore, it activated axonal regeneration by inhibiting scar tissue formation and regulating CD4+. + T cell transformation supports neurogenesis.

The present invention discloses a bioactive scaffold for slowly releasing Apt19S to recruit endogenous stem cells and guide the straight regeneration of central nervous system axons and its application. The bioactive scaffold is composed of acellular optic nerve (DON) and aptamer Apt19S, and its preparation method comprises the following steps: 1. preparing a DON scaffold. 2. activating the carboxyl group on the surface of the DON scaffold. 3. The DON scaffold is combined with amino-modified Apt19S through an amidation reaction to obtain the DON‑Apt19S scaffold (abbreviated as DON‑A). This bioactive scaffold can continuously release Apt19S, recruit ALPL-positive endogenous neural stem cells and mesenchymal cells, guide the straight regeneration of central nervous system axons, and provide a microenvironment for neurogenesis and angiogenesis for in situ spinal cord repair. The bioactive scaffold has important transformation prospects and application value in the repair of central nervous system injuries.

The present application relates to a composition using an endothelin B receptor agonist, such as Sovastatin (N-succinyl-[Glu9, Ala11, 15] endothelin 1, IRL-1620), for promoting cell proliferation and protecting the original neuroepithelium of cochlear and vestibular cells located within the ear sac. The pharmaceutical composition is systemically administered by means of tympanic membrane puncture, cochleostomy or intravenous or intramuscular injection. A pharmaceutical composition for the treatment of sensorineural hearing loss and vestibular disorders caused by inner ear cell degeneration, the pharmaceutical composition comprising a compound of an endothelin analogue, the use being treated by the neuroprotection and neurogenesis mechanism of cochlear vestibular hair cells and synapses.

The present disclosure relates to the use of compounds of formula (I), compounds of formula (II), and related analogs for enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex), and to methods of enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex). And other methods and uses related thereto.

The present invention discloses a scaffold-gel composite central nervous system repair material for specifically attracting and incubating endogenous neural stem cells and its application. The composite central nervous system repair material is composed of a decellularized optic nerve scaffold, a decellularized spinal cord hydrogel, neurotrophic factors, and the aptamer Apt19S. The above-mentioned scaffold can continuously release Apt19S and neurotrophic factors, recruit a large number of endogenous stem cells, and provide a neurogenesis microenvironment and physical support performance support for in situ spinal cord repair. The composite central nervous system repair material can be transplanted into the spinal cord injury site to repair spinal cord injury, and can also be transplanted into the optic nerve or brain injury site to repair central nervous system injury.

The invention discloses a pharmaceutical composition for promoting neuron neogenesis and a method for promoting neuron neogenesis by using a gastrodia elata extract or an adenosine analogue. The gastrodia elata extract comprises gastrodin, gastrodigenin, a parishins compound, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde (4-hydroxybenzaldehyde). The invention also discloses a method for promoting neuron neogenesis by using the gastrodia elata extract or the adenosine analogue. The gastrodia elata extract provided by the invention has aging-retarding activity on nerve cells and can induce mouse hippocampal neuronal neogenesis.

A system and method for dual-task neurological therapy using a combination of primary and secondary tasks to facilitate neurogenesis and neuroplasticity in targeted regions of the brain using computer-enhanced dual-task analysis and treatment. The system and method involve having a subject engage in primary and secondary tasks at levels of intensity or stress associated with increased neurogenesis and neuroplasticity. In some embodiments, novel secondary tasks are selected to vary the tasks to help with neurogenesis and neuroplasticity, novel content for the secondary tasks are generated by a generative AI model, adjustments are made to the tasks during performance using a feedback mechanism to adjust for the abilities and performance of the patient, and empathetic feedback is generated by a generative AI model and provided to the patient during performance of tasks.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.

Injecting botulinum toxin directly into the clitoris can treat various sexual dysfunctions and improve sexual satisfaction in many women. Without wishing to be bound by this hypothesis, these effects of botulinum toxin may act by, inter alia, increasing arterial blood flow within the clitoris via vasodilation, neovascularization within the clitoris, neurogenesis within the clitoris, changing autonomic tone, and activating the mid-hypothalamus.

A method and structure are disclosed. An example neural network is provided comprising multiple neurons including a subset of neurons comprising a majority of the multiple neurons, wherein each neuron of the subset of neurons has upstream neurons and downstream neurons interconnected through connections in a manner such that the connections for each neuron to other neurons are unconstrained within defined limits so that the neural network has an amorphous shape that is not predefined within the constrained limits. A neurogenesis method for creating the example network is disclosed.

The application discloses application of human amniotic epithelial stem cells in preparation of a medicine for treating depressive diseases. The human amniotic epithelial stem cells are obtained by mechanically separating the inner surface amnion of discarded placental tissue, and then subjected to trypsin digestion, centrifugation, resuspension and harvesting in sequence after washing; and a human amniotic epithelial stem cell scheme for treating depression; the cells are widely sourced, free of ethical controversy, low in immunogenicity and non-tumorigenic, and provide a new safe and effective approach for treating depression; the cell preparation can be administered through intravenous injection, intrathecal injection or nasal delivery, and the mechanism of action is to inhibit the overactivation of glial cells, reduce the depressive-related neuroinflammatory response, and thus improve the neuronal microenvironment. The application can effectively promote hippocampal neurogenesis (increase in DCX positive cells), regulate 5-hydroxytryptaminergic neurons and glutamatergic neuron activity, restore the steady state of neural networks, and significantly improve the depressive behavior of model mice.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

The application belongs to the technical field of biotechnology, and specifically discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and provides overexpression of a neurogenesis-promoting transcription factor and knockdown of an inducible hindering factor, which are expected to be effective methods for improving transdifferentiation efficiency and generating more newborn neurons, and thus are widely applied to treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases and traumatic diseases of the central nervous system.

A system and method for targeted treatment of human brain function using a combination of physical and mental activity to cause neurogenesis and neuroplasticity in targeted regions of the brain using computer-enhanced dual-task analysis and treatment. The system and method involve having a subject engage in physical and mental activities at levels of intensity or stress associated with increased neurogenesis and neuroplasticity, the mental activities being associated with certain brain regions intended to be targeted by the treatment, wherein the physical and mental activities are assigned based on dual-task analyses of the subject's brain function and machine learning algorithms trained to optimize the stress levels associated with the physical and mental activities to maximize neurogenesis and neuroplasticity. The physical and mental activities may be continuously adjusted to ensure that the subject remains in appropriate ranges for neurogenesis and neuroplasticity for the brain region or regions being targeted for treatment.

The present invention discloses a method and system for predicting the development of early cortical folds in the human brain based on a neural network model, which falls into the interdisciplinary field of artificial intelligence and brain science. The method extracts a three-dimensional skeleton of cortical folds using brain negative model skeleton technology, and uses a β-VAE model to capture the complex pattern of folds changing with gestational age, achieving accurate predictions from 30 to 40 weeks of gestation. The method uses a large amount of MRI imaging data to train the model to ensure the accuracy of the prediction results. The system modular design of the method improves scalability and maintainability, and the computer implementation ensures real-time and accuracy. The present invention solves the problem of the lack of neurogenesis heterogeneity information in existing models, provides a new approach for studying the development of early cortical folds in the human brain, and has broad application prospects, such as evaluating the neurodevelopment of premature infants and early diagnosis of diseases.

The invention discloses an application of CB1R as a target in treating mental disorder caused by stress. Experimental research finds that selective overexpression of the hippocampus CB1R possibly promotes proliferation of newborn cells in the hippocampus and differentiation and maturation of newborn neurons by effectively protecting neurogenesis in the hippocampus of a stress rat, so that the effect of improving depression-like behaviors of the stress rat is achieved. The invention provides a novel treatment strategy for promoting hippocampal neurogenesis by using the hippocampal CB1R so as to realize depression resistance.